257 related articles for article (PubMed ID: 29928946)
1. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.
Stecklein SR; Park M; Liu DD; Valle Goffin JJ; Caudle AS; Mittendorf EA; Barcenas CH; Mougalian S; Woodward WA; Valero V; Sahin AA; Yang WT; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):568-577. PubMed ID: 29928946
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes.
Grills IS; Kestin LL; Goldstein N; Mitchell C; Martinez A; Ingold J; Vicini FA
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):658-70. PubMed ID: 12788171
[TBL] [Abstract][Full Text] [Related]
3. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
Kim N; Kim JY; Park W; Cho WK; Kim TG; Im YH; Ahn JS; Lee JE; Nam SJ; Kim SW; Yu J; Chae BJ; Lee SK; Ryu JM; Park YH; Kim H
Breast; 2023 Dec; 72():103594. PubMed ID: 37924622
[TBL] [Abstract][Full Text] [Related]
4. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
Gingras I; Holmes E; De Azambuja E; Nguyen DH; Izquierdo M; Anne Zujewski J; Inbar M; Naume B; Tomasello G; Gralow JR; Wolff AC; Harris L; Gnant M; Moreno-Aspitia A; Piccart MJ; Azim HA
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376188
[TBL] [Abstract][Full Text] [Related]
5. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
Jagsi R; Barlow WE; Woodward WA; Connolly E; Mahtani R; Shumway D; Speers C; Stecklein SR; Zeidan Y; Zhang H; Sharma P; Pusztai L; Hortobagyi GN; Kalinsky K
JAMA Oncol; 2023 Aug; 9(8):1083-1089. PubMed ID: 37410451
[TBL] [Abstract][Full Text] [Related]
7. The Role of the Neo-Bioscore Staging System in Guiding the Optimal Strategies for Regional Nodal Irradiation Following Neoadjuvant Treatment in Breast Cancer Patients with cN1 and ypN0-1.
Cao L; Xu C; Kirova YM; Cai G; Cai R; Wang SB; Shen KW; Ou D; Chen JY
Ann Surg Oncol; 2019 Feb; 26(2):343-355. PubMed ID: 30519764
[TBL] [Abstract][Full Text] [Related]
8. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
10. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
11. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
[TBL] [Abstract][Full Text] [Related]
12. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Mamounas EP; Anderson SJ; Dignam JJ; Bear HD; Julian TB; Geyer CE; Taghian A; Wickerham DL; Wolmark N
J Clin Oncol; 2012 Nov; 30(32):3960-6. PubMed ID: 23032615
[TBL] [Abstract][Full Text] [Related]
13. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
15. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
16. Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation.
Fodor J; Toth J; Major T; Polgar C; Nemeth G
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):281-7. PubMed ID: 10760420
[TBL] [Abstract][Full Text] [Related]
17. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
[TBL] [Abstract][Full Text] [Related]
18. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
19. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
20. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
